We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Omnicell, Inc.'s (OMCL - Free Report) increasing cost of production continues to hamper the company’s margin performance. Weak hospital spending trends and tough competition also pose threats. Currently, Omnicell carries a Zacks Rank #4 (Sell).
The company has adopted several strategies to drive its top line including portfolio expansion, acquisitions and further penetration in the medication adherence market. Thus, the company continues to battle escalating costs. Also, the company continues to expect higher costs in the upcoming quarters, stemming from the integration of new acquisitions and the expenses related to the XT series and IV workflow.
In the first quarter, total cost of revenues increased 7.9% year over year. Selling, general, and administrative expenses too rose 9.9% in the quarter. Further, the company’s second-quarter 2021 guidance includes additional freight costs, given pandemic-induced difficult global market conditions. This might impact margins in the second quarter.
Further, hospital purchases continue to remain a challenge for the small community hospitals compared with the bigger ones owing to financial constraints. This is reflected in the data provided by the company, which suggests that 70% of small hospitals in the United States deploy automated dispensing cabinets versus 96% and 99% for medium and large hospitals, respectively.
Intense competition in the medication management and supply chain solutions market is another major downside.
On a positive note, over the past six months, Omnicell’s shares have outperformed the industry it belongs to. The stock has gained 19.5% against the industry’s 34.3% decline.
Omnicell exited the first quarter with better-than-expected revenues and earnings. The top line rose year over year on growth across both the operating segments. In the quarter, there has beenarecord increase in the number of long-term sole-source contracts with the addition of top 300 U.S. health systems. One of the new wins is the largest single sole-source agreement in Omnicell's history. A top 10 U.S. health system has chosen Omnicell to help them design and implement complex pharmacy workload.
Overall, the company’s optimism about the gradual resumption of elective surgeries is encouraging. The company is advancing autonomous pharmacy by expanding portfolio and investing in the digital cloud-based platform. The raised adjusted EPS guidance also buoys optimism.
Image: Bigstock
Omnicell (OMCL) Faces Lingering Cost Woes, Fierce Competition
Omnicell, Inc.'s (OMCL - Free Report) increasing cost of production continues to hamper the company’s margin performance. Weak hospital spending trends and tough competition also pose threats. Currently, Omnicell carries a Zacks Rank #4 (Sell).
The company has adopted several strategies to drive its top line including portfolio expansion, acquisitions and further penetration in the medication adherence market. Thus, the company continues to battle escalating costs. Also, the company continues to expect higher costs in the upcoming quarters, stemming from the integration of new acquisitions and the expenses related to the XT series and IV workflow.
In the first quarter, total cost of revenues increased 7.9% year over year. Selling, general, and administrative expenses too rose 9.9% in the quarter. Further, the company’s second-quarter 2021 guidance includes additional freight costs, given pandemic-induced difficult global market conditions. This might impact margins in the second quarter.
Further, hospital purchases continue to remain a challenge for the small community hospitals compared with the bigger ones owing to financial constraints. This is reflected in the data provided by the company, which suggests that 70% of small hospitals in the United States deploy automated dispensing cabinets versus 96% and 99% for medium and large hospitals, respectively.
Intense competition in the medication management and supply chain solutions market is another major downside.
Omnicell, Inc. Price
Omnicell, Inc. price | Omnicell, Inc. Quote
On a positive note, over the past six months, Omnicell’s shares have outperformed the industry it belongs to. The stock has gained 19.5% against the industry’s 34.3% decline.
Omnicell exited the first quarter with better-than-expected revenues and earnings. The top line rose year over year on growth across both the operating segments. In the quarter, there has beenarecord increase in the number of long-term sole-source contracts with the addition of top 300 U.S. health systems. One of the new wins is the largest single sole-source agreement in Omnicell's history. A top 10 U.S. health system has chosen Omnicell to help them design and implement complex pharmacy workload.
Overall, the company’s optimism about the gradual resumption of elective surgeries is encouraging. The company is advancing autonomous pharmacy by expanding portfolio and investing in the digital cloud-based platform. The raised adjusted EPS guidance also buoys optimism.
Key Picks
A few better-ranked stocks from the Medical-Products industry include Envista Holdings Corporation (NVST - Free Report) , HillRom Holdings, Inc. and BellRing Brands, Inc. (BRBR - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Envista Holdings has a long-term earnings growth rate of 26.4%.
HillRom Holdings has a long-term earnings growth rate of 7.9%.
BellRing Brands has a long-term earnings growth rate of 25.3%.